Classes
DEA Class; Rx
Common Brand Names; Mavik
- ACE Inhibitors
Description
Oral ACE inhibitor; structurally similar to enalapril, requiring hydrolysis for activity; used once daily for HTN and to reduce cardiovascular morbidity and mortality following AMI.
Indications
Indicated for the treatment of hypertension.
Contraindications
Hypersensitivity
History of hereditary or angioedema associated with previous ACE inhibitor treatment
Coadministration of neprilysin inhibitors (eg, sacubitril) with ACE inhibitors may increase angioedema risk; do not administer ACE inhibitors within 36 hr of switching to or from sacubitril/valsartan
Bilateral renal artery stenosis
Do not coadminister with aliskiren in patients with diabetes mellitus or with renal impairment (ie, GFR <60 mL/min/1.73 m²)
Adverse Effects
Cough (1.9-35%)
Elevated Uric Acid (15%)
Hypotension (1-11%)
Syncope (5.9%)
Hyperkalemia (5.3%)
Hypocalcemia (4.7%)
Stroke (3.8%)
Bradycardia (1-5%)
Dizziness (1.3-2.3%)
Angioedema
ARF if renal artery stenosis
Warnings
Less effective in Blacks
Excessive hypotension if concomitant diuretics, hypovolemia, hyponatremia
Renal impairment may occur
Coadministration with mTOR inhibitors (eg, temsirolimus, sirolimus, everolimus) may increased risk for angioedema
Neutropenia/agranulocytosis reported
Cough may occur within the first few months
Cholestatic jaundice may occur
Risk of hyperkalemia, especially in renal impairment, diabetes melliuts, or coadministration with potassium-elevating drugs
ACE inhibition also causes increased bradykinin levels which putatively mediates angioedema; higher incidence of angioedema in black than nonblack patients
Dual blockade of the renin angiotensin system with ARBs, ACE inhibitors, or aliskiren associated with increased risk for hypotension, hyperkalemia, and renal function changes (including acute renal failure) compared to monotherapy
Intestinal angioedema reported in patients treated with ACE inhibitors; it should be included in differential diagnosis of patients, taking ACE inhibitors and presenting with abdominal pain
Pregnancy and Lactation
Pregnancy Category: C (1st trimester); D (2nd/3rd trimesters)
Lactation: possibly excreted in breast milk; nursing not recommended
Maximum Dosage
8 mg/day PO for hypertension; 4 mg/day PO for heart failure, acute myocardial infarction, or postmyocardial infarction.
8 mg/day PO for hypertension; 4 mg/day PO for heart failure, acute myocardial infarction, or postmyocardial infarction.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Trandolapril
tablet
- 1mg
- 2mg
- 4mg